Pink Sheet Team
Editorial Team

The policy and regulatory insights advantage for biopharma decision-makers around the globe.
Latest From Pink Sheet Team
Pink Sheet Podcast: Moderna CEO On Capitol Hill, Xtandi March-In Rights, Tofersen Adcomm In ALS
Pink Sheet reporter and editors discuss Moderna CEO’s Stéphane Bancel’s defense of his company and COVID-19 vaccine pricing at the Senate Health, Education, Labor and Pensions Committee, the NIH denying a petition to use government march-in rights for Xtandi, and Tofersen receiving a positive US FDA advisory committee recommendation for use in ALS.
Pink Sheet Podcast: RSV Vaccine Questions, Lilly Lowers Insulin Cost, Orphan Drug Act Changes
Pink Sheet reporters and editors discuss US FDA advisory committee members’ concerns about two proposed RSV vaccines, Lilly’s plan to lower the cost of its insulin products, proposed changes to the Orphan Drug Act, and the departure of the influential leader of the FDA’s neuroscience office.
Publisher’s Spotlight: Citeline Awards 2023 Finalists Announced
We are delighted to announce the shortlist for the seventh annual Citeline Awards, recognizing clinical and research excellence across the biopharmaceutical, CRO and diagnostics industries.
Pink Sheet Podcast: Limiting Medicare Price Negotiation, More US FDA Adcomm And COVID-19 Vaccine Concerns
Pink Sheet reporters and editors discuss the impact of PhRMA’s new push to limit Medicare price negotiations, Congress’ interest in FDA advisory committee reforms, and concerns about the COVID-19 vaccine strain selection process.
Pink Sheet Podcast: More US FDA Communication Problems, 2022 Novel Approval Trends, Cancer Drug Dosing Guidance
Pink Sheet reporters and editors discuss concerns related to the FDA’s announcement of a COVID-19 vaccine safety investigation, 2022 novel drug approval data, and a new guidance on cancer vaccine dose optimization.
Pink Sheet Podcast: Leqembi Approved, Medicare Price Negotiation Timeline, AAM CEO Departure
Pink Sheet reporters and editors discuss the take-aways from Leqembi’s approval as an Alzheimer’s treatment, the new timeline for information collection and comment on Medicare price negotiations, and the reasons a generic drugs trade association CEO departed.